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Abstract
The Ovarian Cancer Association Consortium selected 7 candidate single nucleotide polymorphisms
(SNPs), for which there is evidence from previous studies of an association with variation in ovarian
cancer or breast cancer risks. The SNPs selected for analysis were F31I (rs2273535) in AURKA,
N372H (rs144848) in BRCA2, rs2854344 in intron 17 of RB1, rs2811712 5′ flanking CDKN2A,
rs523349 in the 3′ UTR of SRD5A2, D302H (rs1045485) in CASP8 and L10P (rs1982073) in
TGFB1. Fourteen studies genotyped 4,624 invasive epithelial ovarian cancer cases and 8,113 controls
of white non-Hispanic origin. A marginally significant association was found for RB1 when all
studies were included [ordinal odds ratio (OR) 0.88 (95% confidence interval (CI) 0.79-1.00) p =
0.041 and dominant OR 0.87 (95% CI 0.76-0.98) p = 0.025]; when the studies that originally
suggested an association were excluded, the result was suggestive although no longer statistically
significant (ordinal OR 0.92, 95% CI 0.79-1.06). This SNP has also been shown to have an association
with decreased risk in breast cancer. There was a suggestion of an association for AURKA, when one
study that caused significant study heterogeneity was excluded [ordinal OR 1.10 (95% CI 1.01-1.20)
p = 0.027; dominant OR 1.12 (95% CI 1.01-1.24) p = 0.03]. The other 5 SNPs in BRCA2, CDKN2A,
SRD5A2, CASP8 and TGFB1 showed no association with ovarian cancer risk; given the large sample
size, these results can also be considered to be informative. These null results for SNPs identified
from relatively large initial studies shows the importance of replicating associations by a consortium
approach.
Keywords
association study; neoplasms; ovarian cancer; replication; single nucleotide polymorphism
Known high penetrance susceptibility genes such as BRCA1 and BRCA2 explain less than 40%
of the excess familial risk of epithelial ovarian cancer.1 The unexplained familial risk could
be due to common low or moderately penetrant alleles.2 To identify these alleles, genetic
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association studies comparing frequencies of single nucleotide polymorphisms (SNPs)
between cases and controls have been widely used, leading to the identification of several
moderate risk alleles for some cancer types.3-5 However, most reported associations have not
been replicated by subsequent studies,6,7 demonstrating that large sample sizes are needed to
both identify and characterize as well as to refute genetic associations at convincing levels of
statistical significance.8,9 A consortium approach, in which several different studies are
combined for the analysis of candidate disease-associated alleles offers a possible solution with
improved power and protection from publication bias.10
We have established the Ovarian Cancer Association Consortium (OCAC) in an effort to clarify
the role of previously reported candidate SNPs associated with ovarian cancer risk. The OCAC
is an international collaboration comprising more than 5,000 ovarian cancer cases and 9,000
controls.11 An important role of the OCAC and other consortia is replication of findings from
individual member studies. Here, we evaluated 7 SNPs that reportedly confer variable ovarian
and breast cancer risks in the genes AURKA, BRCA2, CASP8, CDKN2A, RB1, SRD5A2 and
TGFB1 (Table I).11-13,15,17,19
Many types of cancers, including those of the breast, colon, prostate, endometrium and ovary
show amplification and over-expression of AURKA, which encodes a serine/threonine kinase
AURORA-A. A candidate SNP (rs2273535) in AURKA has been associated with an increased
ovarian cancer risk12 and other cancers.20 This SNP causes a nonconservative amino acid
substitution F31I in an evolutionary conserved region of the NH2 terminal domain of
AURKA. This domain has been proposed to function in translocation of AURKA from
cytoplasm to centrosome during mitosis.21 The I31 allele of AURKA has been shown to have
reduced binding to UBE2N, and also transforms rat cells more potently than the F31 allele.22
Deleterious mutations in the BRCA2 gene confer high-risk susceptibility to ovarian cancer.
BRCA2 is involved in DNA double strand break repair pathways and is critical to maintaining
genomic integrity. The SNP rs144848 creates a nonconservative amino acid substitution
(N372H) in a region of the protein that has been shown to interact with the histone
acetyltransferase P/CAF.14 The HH genotype has been associated with increased risk of both
ovarian and breast cancer.13,14 However, this latter result was not confirmed in a consortium
study of more than 15,000 breast cancer cases and 15,000 controls.18
Retinoblastoma 1 (RB1) is somatically mutated and/or shows loss of function in many cancer
types. Approximately 60% of epithelial ovarian cancers show abnormal RB1 function; and
survival in ovarian cancer cases showing intact RB1 may be significantly better than for cases
in which the RB1 pathway is abrogated.23,24 A SNP in intron 17 (rs2854344) is contained
within an open reading frame that encodes a G protein coupled receptor P2RY5 in reverse
orientation to the transcription of RB1.25 The rare allele of this SNP may confer a protection
against both breast and ovarian cancer.15,16
The cyclin-dependent kinase inhibitor 2A (CDKN2A) gene, functions in the cell cycle control
pathway, and a 5′ flanking SNP (rs2811712) was associated with a marginally increased risk
of ovarian cancer for the rare homozygote group.11 This SNP is also of interest, because it
may confer susceptibility to aging.26 There is substantial evidence of a role for CDKN2A in
ovarian tumor development. The gene is frequently deleted in ovarian cancer cell lines and
primary tumors, and shows loss of expression and hyper-methylation.27 Homozygous
deletions of CDKN2A and the neighboring CDKN2B genes have been associated with a poor
prognosis in ovarian cancer patients.28
The product of the steroid-5-α-reductase (SRD5A2) gene catalyses the conversion of
testosterone to the more biologically active dihydrotestosterone. Testosterone may have a role
in causing polycystic ovary disease (PCOS), a condition that is characterized by high levels of
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androgen29 and has been associated with ovarian cancer development.30 The nonsynonymous
SNP V89L (rs523349) of SRD5A2 appears to affect the rate of testosterone conversion.31 In
a recent study, rs523349 was associated with an increase in ovarian cancer risk although another
SNP (rs632148; in the 3′ UTR) in linkage disequilibrium (r2 = 0.9) showed no association.17
There are known similarities in the genetic predisposition to both breast and ovarian cancer;
for example, high risk mutations in the genes BRCA1 and BRCA2 as well as several SNPs
showing associations with both breast and ovarian cancer risk.1,15,16 Therefore, we also
selected 2 SNPs as candidates that had been shown to have a highly significant association
with breast cancer risk in a large consortium study.19 CASP8 encodes caspase 8, one of the
initiator caspases that transduce apoptotic signals from the death receptors at the cell surface.
The SNP rs1045485 results in an amino acid change D302H in exon 12. This SNP is associated
with a reduced risk in breast cancer in a dose-dependent manner,18,32-34 a result that was
confirmed in a larger study.19 Finally,transforming growth factor β1(TGFB1) is a dimeric
cytokine and a potent inhibitor of proliferation of epithelial, endometrial and hematopoietic
cells. It acts as a tumor suppressor, but can also promote tumor progression.35-38 The
rs1982073 SNP causes a L10P amino acid change that has been associated with increased
secretion of TGFB1.39 It was shown to be associated with an increased risk of breast cancer,
18 which was also confirmed in a larger study.19
The purpose of the current study was to evaluate the ovarian cancer risks associated with the
7 SNPs described above in a coordinated analysis of ovarian cancer case-control studies from
USA, Europe and Australia. These studies provided data on up to 4,624 invasive cases and
8,113 controls of white non-Hispanic origin and up to 5,317 invasive epithelial ovarian cancer
cases and 9,092 controls including all races and ethnicities.
Material and methods
Study subjects
In total, 14 different ovarian cancer case-control studies contributed data to this study (Table
II; see also Supplementary Table 1 and Ref. 11). Twelve studies used population-based
ascertainment for cases and controls, 1 study was clinic-based, and 1 was a case-control study
nested within a cohort. All studies received ethical committee approval, and all study subjects
provided informed consent. Key clinical and questionnaire data on study participants including
case-control status, ethnicity/race, tumor behavior, histologic subtype, age at diagnosis/
interview, history of prior cancers were merged into a common dataset. The data were checked
for consistency and completeness, and followed-up with individual study investigators.
Individuals missing age or tumor behavior and individuals with a prior history of ovarian cancer
were excluded. The combined data set comprised 5,317 invasive epithelial ovarian cancer
cases, 9,092 controls (Table II). Of these, 88% were of white non-Hispanic origin; 4,624
invasive cases and 8,113 controls. Other participants were white Hispanic (41 cases and 69
controls), black non-Hispanic (112 cases and 164 controls), Asian non-Hispanic (199 cases
and 268 controls), other ethnicities (149 cases and 287 controls); 191 cases and 192 controls
were missing ethnicity information. An additional 1,025 cases classified as having borderline/
low malignant potential tumors were available, of which 830 were of white non-Hispanic
origin.
Genotyping
Seven SNPs were analyzed; AUKRA F31I rs2273535, BRCA2 N372H rs144848, RB1 intron
17 rs2854344, CDKN2A 5′ flanking rs2811712, CASP8 D302H rs1045485, TGFB1 L10P
rs1982073, SRD5A2 3′ UTR rs632148. For SRD5A2 a TaqMan™ assay could not be designed
Ramus et al. Page 4
Int J Cancer. Author manuscript; available in PMC 2009 July 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
for the V89L rs523349 SNP that had shown an association with ovarian cancer and therefore
a tagged SNP (r2 = 0.9) in the 3′ UTR (rs632148) was used instead.17 Genotyping was
performed at 10 different centers on 384-well plates, and all but 1 study used TaqMan (Applied
Biosystems, Warrington, UK) according to the manufacturer's instructions. Six of the seven
assays were Assays-by-Design™ (Applied Biosystems), while one (CASP8) used custom
primers and probes. Each assay was carried out using 10 ng DNA in a 5μl reaction volume as
described previously.11 One study (AUS; Table II) used iPLEX technology (Sequenom) to
perform genotyping. Genotype data that had been previously reported included AUKRA,
CDKN2A, RB1 and SRD5A2 for the MAL, SEA and STA studies11,12,15,17 and BRCA2 for
the AUS and SEA studies.13
Genotyping quality control
We compared genotype call rates and concordance between studies. We used the following
criteria as measures of acceptable genotyping: (i) >3% sample duplicates included, (ii)
concordance rate for duplicate samples ≥98%, (iii) overall call rate (by study) >95% and (iv)
call rate >90% for each 384-well plate. Studies failing these criteria were excluded for particular
SNPs. Hardy- Weinberg equilibrium (HWE) among white non-Hispanic controls was also used
to assess quality of genotyping. The genotyping of any SNP in a study deviating significantly
from HWE (p < 0.05) were assessed, and the data were excluded if the clustering was found
to be suboptimal. Some studies with minor departures from HWE were included if genotype
clustering was good. Hence, there is variation in the number of studies/samples successfully
genotyped for each polymorphism.
We further assured the quality of genotyping between laboratories by requiring each of the 10
laboratories genotyping the 14 studies, to additionally genotype a panel of CEPH-Utah trios
at each SNP
(http://ccr.coriell.org/Sections/Search/Panel_Detail.aspx?PgId=202&Ref=HAPMAPPT01).
The panel included 90 DNA samples from 30 trios, 5 duplicate samples and a negative template
control in a 96-well plate format. This allowed for assessment of consistency across studies,
with HapMap published genotypes, and with Mendelian inheritance. The average call rate for
the HAPMAP plate was 97.8% (range 95.8%-98.9% across the 10 centers and 97.1%-99.3%
across the 7 SNPs). The concordance of genotypes between the centers showed problems with
calling of the CASp8 assay in the HAW study and the AURKA assay for NCO study. Therefore,
these data were excluded for these SNPs, correcting concordance rates to 99.95%. When a
study was not concordant (>1/90 discordant) for a SNP for the HAPMAP plate, the case-control
data were also excluded.
Statistical analysis
Genotypes obtained from the study participants were used to estimate allele frequencies in
cases and controls. We assessed departures from HWE in the control subjects using a Pearson
goodness-of-fit test, or a Fisher exact test for SNPs with minor allele frequencies less than
0.05.40 Data were summarized using frequencies and percentages for categorical variables,
and means and standard deviations for continuous variables. We assessed associations of each
SNP with risk of ovarian cancer using multivariate logistic regression analysis to estimate odds
ratios (ORs) and 95% confidence intervals (CIs). Primary analyses were carried out assuming
an ordinal (log-additive) genotypic relationship, using simple tests for trend within the logistic
regression models. However, we also examined associations between each SNP and ovarian
cancer risk separately for heterozygote and rare homozygote subjects, with subjects
homozygous for the major allele serving as the referent group. Analyses were carried out
overall, as well as by study site and race. We conducted SNP-specific formal tests of
heterogeneity of risk across study site by including study site, genotype and the corresponding
interaction terms in a logistic regression model, and testing the statistical significance of the
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interaction term. Further analyses of subsets of cases stratified by cancer stage (local, regional
and distant) and histology (serous, mucinous, endometrioid, clear cell, mixed cell and other/
unknown epithelial) were performed. Study site-specific logistic regression analyses adjusted
for the potential confounding effects of age. All other logistic models described above were
adjusted for both age and study site. We adjusted for site using 2 different methods. First, we
included study site as a fixed effect covariate in the logistic regression models. Second, we
included site as a random effect using nonlinear mixed effects modeling approaches. Analyses
were conducted both with and without the inclusion of previously reported data; when included,
raw data were used rather than summary data or meta-analytic methods. All statistical tests
were 2-sided, and all analyses were conducted using the SAS system (SAS Institute, Cary,
NC).
Results
In total, we genotyped 4,624 invasive ovarian cancer cases, 8,113 controls and 830 cases with
borderline/low malignant potential tumors of white non-Hispanic origin and 693 invasive
cases, 979 controls and 195 borderline/low malignant potential cases of other races and
ethnicities (Table II). Genotype frequencies and results for tests for deviation from HWE for
each study are given in Supplementary Table 2. Minor allele frequencies for all controls were
consistent across studies for white non-Hispanic participants, but differed among the other
ethnicities.
The results presented in this article are based on analysis of white non-Hispanic individuals.
Summary ordinal OR for all white non-Hispanic samples are given in Table III. For 5 of the
SNPs (rs2811712 in CDKN2A, rs2854344 in RB1, rs144848 in BRCA2, rs2273535 in
AURKA, rs632148 in SRD5A2), these data are a combination of new genotype data and the
original genotyping data that suggested associations.11-13,15,17 The remaining 2 SNPs
(rs2811712 in CASP8 and rs2811712 in TGFB1) have not previously been genotyped in OCAC
studies.
We found no evidence of association for AURKA, BRCA2, CASP8, CDKN2A, SRD5A2 and
TGFB1 (Fig. 1). However, we did find a borderline-significant association with rs22854344
in RB1. With the ordinal model, the OR was 0.88 (95% CI 0.79-1.00; p = 0.041). This SNP
was also suggestive using the dominant model (OR 0.87: 95% CI 0.76-0.98; p = 0.025) (Fig.
2 and Supplementary Table 3).
We performed tests for heterogeneity across studies for the white non-Hispanic subjects, and
found evidence of heterogeneity for AURKA (p = 0.005). This was driven by 2 studies, which
suggested associations in opposite directions, for the Mayo Clinic study (MAY, p = 0.004) and
for the Stanford study (STA, p, = 0.04). Therefore, we reanalyzed the data excluding both or
either of these studies. When both studies were excluded, the OR for AURKA was 1.06 (95%
CI 0.97-1.16; p = 0.16; test for heterogeneity p = 0.72); when STA only was excluded, the OR
was 1.01 (95% CI 0.93-1.10; p = 0.76; test for heterogeneity p = 0.03); when MAY only was
excluded, the OR was 1.10 (95% CI 1.01- 1.20; p = 0.027; test for heterogeneity p = 0.31). The
dominant model was also significant when MAY was excluded OR (1.12: 95% CI 1.01-1.24;
p = 0.03).
For 5 SNPs that were previously genotyped in populations from the OCAC (AUKRA,
CDKN2A, RB1 and SRD5A2 for MAL, SEA and STA11,12,15,17 and BRCA2 for AUS and
SEA13), we repeated the analyses after excluding the original published data that had suggested
evidence of an association. Summary ORs for the ordinal model with exclusion of these data
are given in Table III. There was no association for any of these SNPs after exclusion of the
initial data. For RB1, which had shown evidence of association in the combined analysis, the
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OR for the ordinal model was 0.92 (95% CI 0.79-1.06; p = 0.233), and for the dominant model
was 0.92 (95% CI 0.79-1.07; p = 0.254). Thus there remains a suggestion of an association for
this SNP.
We studied variation in the genotypic risks by clinical features of disease. Histological subtype
data were available from 4,532 white non-Hispanic invasive cases; 2,508 (55.3%) were serous,
345 (7.6%) were mucinous, 737 (16.3%) were endometrioid, 381 (8.4%) were clear cell and
112 (2.5%) were mixed histological subtypes; 449 (9.9%) were described as other/unknown.
Stage data were available for 3,400 invasive cases, of which 741 (21.8%) were classified as
local, 640 (18.8%) as regional and 2,019 (59.3%) as distant. We found no significant
differences in risk by either histological subtype or stage (data not shown). Finally, we looked
for associations with borderline disease. There were 830 white non-Hispanic individuals with
borderline/low malignant potential tumors. We found a marginally significant association for
CASP8 [OR 1.18 (95% CI 1.00-1.39; p = 0.056)] (Supplementary Table 4).
All combined analyses reported above included study site as a fixed effect covariate. We ran
a series of secondary analyses accounting for the effects of site by including it as a random
effect term, and found nearly identical results (not shown).
Discussion
The OCAC has analyzed 7 candidate SNPs for ovarian cancer risk association in 14 case-
control studies from USA, Europe and Australia. For 5 of these SNPs (in AURKA, BRCA2,
CDKN2A, RB1 and SRD5A2), there is previous evidence from the published literature that they
are associated with variable risks of epithelial ovarian cancer.11-13,15,17 The remaining 2
SNPs (CASP8 and TGFB1) were considered candidate ovarian cancer susceptibility alleles,
because they have been significantly associated with breast cancer risk variation in a large
consortium study.19
After combining the different studies, 4,624 ovarian cancer cases and 8,113 controls, all of
whom were white non-Hispanic, were analyzed. This represents the largest pooled genotyping
of ovarian cancer case-control studies yet published. We found borderline evidence of
association for a SNP in intron 17 of RB1 (p = 0.025). This SNP has been shown to be associated
with decreased risk of both breast and ovarian cancer.15,16 Many studies have found that RB1
and the pathways in which it functions, are frequently altered in ovarian cancers.23,24 We also
found marginal evidence for a coding nonsynonymous SNP (F31I) in AURKA, when a single
study responsible for causing heterogeneity between studies was removed from the analysis
(p = 0.03). Contrary to the previously published data, there was no association with ovarian
cancer risk for the 3 other SNPs; neither was there evidence that the SNPs in CASP8 and
TGFB1, that are associated with breast cancer risk, have a similar effect in ovarian cancer.
The original reports for AURKA, BRCA2, CDKN2A, RB1 and SRD5A2 had been generated
from the analysis of case-control populations that are part of the OCAC. It has been suggested
that a combined analysis with adjustment for multiple testing has more power than a replication
analysis.41 Neither RB1 nor AURKA were significantly associated with ovarian cancer risk
after adjusting for multiple testing. Most polymorphisms that show moderately significant
associations will be false positives, because the number of polymorphisms throughout the
genome is very high and the prior probability that any polymorphism is associated with disease
is very low. Thus, it has not been possible to validate many initial reportedly positive
associations for disease.6,7,10,11,17 For the 2 putative associations we observed, neither
RB1 nor AURKA were significant without the original data, although the trend for RB1
remained. The initial findings may, therefore, represent false positive associations identified
by chance in studies of small sample size, they may be outlier associations that have “regressed
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to the mean,” or they may exemplify true population heterogeneity that only becomes apparent
when several different study populations are analyzed.
This study highlights the importance of consortium-based approaches for validating suggested
genetic associations from case-control studies, and for identifying novel susceptibility loci for
disease. In addition to dramatically increasing the power of association studies, consortia must
implement stringent data quality and genotyping guidelines; this is likely to minimize reports
of false positive associations.10 The OCAC has established strict genotype quality control
criteria for inclusion in consortium analyses. These include evaluating concordance of
genotyping in 96 control DNA samples between different centers; setting thresholds for
acceptable genotyping pass rates; and including sufficient numbers of duplicate DNA samples
in arrays in order to gauge genotyping accuracy.
These data suggest that there is substantial evidence against a role in susceptibility to ovarian
cancer for some of the SNPs analyzed in this study. The Breast Cancer Association Consortium
have suggested guidelines for excluding SNPs as candidate susceptibility alleles for disease
based on the range of 95% confidence limits.18 Based on the same criteria, this study can, with
reasonable certainty, exclude SNPs in BRCA2, CASP8, CDKN2A, SRD5A2 and TGFB1 from
having more than a small dominant effect; the upper CI limit of the heterozygous OR was less
than 1.12 in all 5 cases. Moderate recessive effects can be excluded for BRCA2, CASP8,
SRD5A2 and TGFB1 as the upper CI limits of the homozygous OR were less than 1.30 in all
cases. The 95% CIs for CDKN2A were much wider (0.89-1.74), and so a moderate recessive
effect cannot be ruled out.
A large body of evidence has emerged suggesting that particular genes and biological pathways
are altered in the development of different histological subtypes of ovarian cancer. For
example, mutations in the KRAS gene are more common in mucinous ovarian cancers; and
germline BRCA1 and BRCA2 mutations appear to predispose to serous ovarian cancers.42
Several association studies have reported different ovarian cancer risks, albeit with borderline
significance, for polymorphisms in candidate genes when cases are stratified by histological
subtype.11,13,15 However, we found no evidence of an effect for any of the SNPs, when
invasive ovarian cancers were stratified by histological subtype. There was limited power,
however, for detecting moderate effects based on histological subtype. We found a marginal
association for rs1045485 in CASP8 when we analyzed borderline ovarian cancer cases; but
the numbers were small and so this may be a chance finding.
False positive results can be obtained due to hidden population stratification. Therefore, we
restricted analysis to white non-Hispanic participants due to significantly different allele
frequencies in different ethnic groups. The only SNP showing heterogeneity between studies
using the white non-Hispanic samples was AURKA. Population heterogeneity has been seen
in another study of this SNP, and it has been suggested to be due to either population
stratification or population-specific linkage disequilibrium with functional variants.43 There
was not, however, population heterogeneity for this SNP in the breast cancer consortium study.
18
In summary, this OCAC analysis of ~4,600 invasive ovarian cancer cases and 8,000 controls
of white non-Hispanic origin for 7 candidate SNPs found a marginally significant result for an
intronic RB1 SNP (rs2854344). The greatly increased sample size of the international
consortium approach to ovarian cancer has clarified the role of other potential candidates, and
suggests that these do not have a significant effect on ovarian cancer risk.
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Figure 1.
Study-specific and combined odds ratios for null SNPs. Forrest plot of the ordinal odd ratios
by study and combined. The overall analyses are adjusted for age and study site, whereas site-
specific analyses adjusted only for age. 95% confidence intervals and sizes of the boxes are
proportional to size of each study (based on white non-Hispanic participants). Order of studies
is in descending order of the total number of white non-Hispanic individuals. If a study did not
genotype a particular SNP, or it failed our QC criteria, this is missing from the plot. Phet = p-
value, test for heterogeneity across study sites. Coding of studies is as in Table II.
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Figure 2.
Study-specific and combined odds ratios for RB1 rs2854344. As for Figure 1.
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